| | | | 12/22/16 | Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement| Transaction to create NASDAQ-listed pharmaceutical company focused on
the development and commercialization of ear, nose, and throat (ENT)
products
Gregory J. Flesher to be Named President and Chief Executive Officer
of the Combined Company
BOSTON, Mass., IRVINE, Calif., & REHOVOT, Israel--(BUSINESS WIRE)--Dec. 22, 2016--
Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) and Otic Pharma Ltd., a
privately-held, clinical-stage pharmaceutical comp... |
|  |  | | 09/08/16 | Tokai Pharmaceuticals Announces Review of Strategic Alternatives| BOSTON--(BUSINESS WIRE)--Sep. 8, 2016--
Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company
focused on developing and commercializing innovative therapies for
prostate cancer and other hormonally driven diseases, today announced
that its Board of Directors has initiated a review of strategic
alternatives for the company focused on maximizing stockholder value.
Potential strategic alternatives that may be explored or evaluated a... |
| | | | 07/29/16 | Tokai Pharmaceuticals Announces Reduction in Force| BOSTON--(BUSINESS WIRE)--Jul. 29, 2016--
Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company
focused on developing and commercializing innovative therapies for
prostate cancer and other hormonally driven diseases, today announced
that it is reducing its workforce by approximately 60 percent, to a
total of 10 full-time equivalent employees, under a plan expected to be
largely completed by the end of the third quarter of 2016. This
... |
| | |
|
Print Page | 
E-mail Page | 
RSS Feeds | 
E-mail Alerts | 
IR Contacts | 
Financial Tear Sheet